These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 16419029

  • 1. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [Abstract] [Full Text] [Related]

  • 2. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S.
    Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
    [Abstract] [Full Text] [Related]

  • 3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [Abstract] [Full Text] [Related]

  • 6. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR, D'Alessio A, Bevilacqua S, Gallo M, Normanno N, De Luca A.
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [Abstract] [Full Text] [Related]

  • 7. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, Yoshitomi S, Takahashi H, Ishibe Y, Ogasawara Y, Doihara H.
    Int J Cancer; 2007 Jan 01; 120(1):181-8. PubMed ID: 17036319
    [Abstract] [Full Text] [Related]

  • 8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 01; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR.
    Clin Cancer Res; 2004 Jul 15; 10(14):4874-84. PubMed ID: 15269164
    [Abstract] [Full Text] [Related]

  • 10. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
    Int J Cancer; 2014 Jun 01; 134(11):2560-71. PubMed ID: 24374738
    [Abstract] [Full Text] [Related]

  • 11. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Jun 01; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 12. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 13. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 14. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM, Chang PY, Tu MG, Lu CC, Kuo SC, Amagaya S, Lee CY, Jao HY, Chen MY, Yang JS.
    Oncol Rep; 2012 Nov 15; 28(5):1799-807. PubMed ID: 22923287
    [Abstract] [Full Text] [Related]

  • 15. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.
    J Hematol Oncol; 2012 Jul 11; 5():16. PubMed ID: 22534171
    [Abstract] [Full Text] [Related]

  • 16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.
    BMC Cancer; 2006 Dec 06; 6():277. PubMed ID: 17150102
    [Abstract] [Full Text] [Related]

  • 19. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
    Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L.
    Cancer Res; 2005 Nov 15; 65(22):10524-35. PubMed ID: 16288045
    [Abstract] [Full Text] [Related]

  • 20. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 15; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.